KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short-term Investments (2016 - 2018)

Travere Therapeutics' Short-term Investments history spans 6 years, with the latest figure at $166.4 million for Q2 2018.

  • For Q2 2018, Short-term Investments fell 19.51% year-over-year to $166.4 million; the TTM value through Jun 2018 reached $166.4 million, down 19.51%, while the annual FY2017 figure was $201.2 million, 6.35% down from the prior year.
  • Short-term Investments reached $166.4 million in Q2 2018 per TVTX's latest filing, down from $202.9 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $250.4 million in Q3 2016 to a low of $5.9 million in Q2 2015.
  • Average Short-term Investments over 5 years is $148.3 million, with a median of $199.7 million recorded in 2016.
  • Peak YoY movement for Short-term Investments: soared 7085.29% in 2014, then decreased 19.51% in 2018.
  • A 5-year view of Short-term Investments shows it stood at $9.6 million in 2014, then surged by 1907.11% to $191.8 million in 2015, then increased by 12.03% to $214.9 million in 2016, then decreased by 6.35% to $201.2 million in 2017, then decreased by 17.32% to $166.4 million in 2018.
  • Per Business Quant, the three most recent readings for TVTX's Short-term Investments are $166.4 million (Q2 2018), $202.9 million (Q1 2018), and $201.2 million (Q4 2017).